Home > > > HPV Testing and Pap Test Market Revenue Forecast, Test Type Segmentation and Industry Outlook

HPV Testing and Pap Test Market Revenue Forecast, Test Type Segmentation and Industry Outlook

Author : Ishika Pathare | Published On : 30 Oct 2026

The global HPV testing and Pap test market size was valued at USD 7.03 billion in 2025 and is projected to grow from USD 7.79 billion in 2026 to USD 17.77 billion by 2034, registering a CAGR of 10.85% during the forecast period from 2026 to 2034. North America dominated the HPV testing and Pap test market with a market share of 38.6% in 2025.

HPV testing and Pap tests are important diagnostic procedures used for the prevention and early detection of cervical cancer. The HPV test identifies human papillomavirus (HPV), a virus that can cause abnormal changes in cervical cells. The Pap test, also known as a Pap smear, examines cervical cells to identify precancerous changes that may develop into cancer if left untreated. Both tests play an important role in women's healthcare by helping doctors identify potential health problems at an early stage. Increasing awareness of cervical cancer, growing screening programs, and technological advancements in diagnostic procedures are supporting market growth.

Market Drivers

High Incidence of Cervical Cancer in Middle-Aged Women

The increasing incidence of cervical cancer among middle-aged women is a major factor driving the HPV testing and Pap test market. According to the World Health Organization (WHO), cervical cancer was the fourth most common cancer among women worldwide, with approximately 570,000 new cases and 311,000 deaths reported in 2018.

Persistent HPV infections are responsible for more than 99% of cervical cancer cases. The average age at diagnosis is around 50 years, with most cases occurring among women aged 35 to 44.

Regular screening helps identify abnormal cervical cells before they develop into cancer. The increasing adoption of Pap tests and HPV testing has contributed to improvements in early diagnosis. According to the American Society of Clinical Oncology (ASCO), cervical cancer incidence decreased by more than 50% between 1975 and 2015 because of increased screening activities. These factors are encouraging healthcare providers to expand screening services and improve access to diagnostic testing.

Increasing Awareness Programs for Cervical Cancer Screening

Growing awareness of cervical cancer prevention is another important factor supporting market growth. Governments, healthcare organizations, and non-profit organizations are introducing screening initiatives to improve early diagnosis and reduce cervical cancer-related deaths.

For instance, the Go Further partnership aims to eliminate AIDS and cervical cancer through screening programs in African countries. The initiative is a collaboration between UNAIDS, the George W. Bush Institute, Merck, and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR).

Women living with HIV are five times more likely to develop cervical cancer than other women. Such initiatives improve access to screening services and encourage women to undergo regular diagnostic testing.

Market Restraints

Changes in Regulatory Guidelines for Cervical Cancer Screening

Changes in regulatory guidelines for cervical cancer screening can restrict market growth. Healthcare organizations periodically update their recommendations regarding screening frequency, age groups, and preferred testing methods.

The reduction in the use of certain Pap smear procedures and stricter screening guidelines introduced by organizations such as the American Cancer Society (ACS) and the American Society for Colposcopy and Cervical Pathology (ASCCP) can affect the demand for traditional testing procedures. These changes may influence purchasing decisions among healthcare providers and diagnostic laboratories.

Market Opportunities

Technological Advancements in Diagnostic Testing

Technological advancements are creating new opportunities in the HPV testing and Pap test market. Healthcare providers are increasingly adopting advanced diagnostic techniques to improve the accuracy and speed of cervical and vaginal cancer screening.

Developments in molecular testing, immunological assays, and automated diagnostic systems are helping improve the detection of HPV infections and abnormal cervical cells.

Artificial intelligence is also creating opportunities for improved screening procedures. In 2019, researchers from the Center for Systems Biology at Massachusetts General Hospital and Harvard Medical School presented a handheld screening device that used AI for HPV detection. The device could identify HPV strains 16 and 18 within approximately two hours.

Market Segmentation

By Test Type

  • HPV Testing

  • Pap Test

The Pap test segment dominates the test type category and is projected to grow at a CAGR of 15.4% during the forecast period. Pap tests identify abnormal and precancerous changes in cervical cells, helping doctors detect potential cancer risks at an early stage.

The widespread use of screening programs and the cost-effective nature of Pap tests have supported their adoption, particularly in low- and middle-income countries. HPV testing also plays an important role by identifying high-risk HPV infections associated with cervical cancer.

By Application

  • Cervical Cancer Screening

  • Vaginal Cancer Screening

Cervical cancer screening dominates the application segment and is projected to grow at a CAGR of 16.7% during the forecast period. The high incidence of cervical cancer and increasing adoption of preventive screening procedures are supporting this segment.

Screening procedures include Pap tests and HPV tests, which help identify abnormal cervical cells and high-risk HPV infections. Increasing awareness of early diagnosis is encouraging more women to undergo regular screening.

By Product

  • Instruments

  • Consumables

  • Services

The consumables segment holds the largest market share and is anticipated to grow at a CAGR of 16.2% during the forecast period. This segment includes testing kits, assays, reagents, sample collection devices, and other accessories used in HPV and Pap testing.

The repeated use of consumables in hospitals, clinics, and diagnostic laboratories supports demand. Increasing screening activities and the growing prevalence of HPV infections are also contributing to segment growth.

By Technology

  • PCR

  • Immunodiagnostics

  • Other Technologies

Other technologies account for the largest revenue contribution in this segment. These include diagnostic procedures such as colposcopy and cystoscopy, which help healthcare professionals examine abnormal tissues and assess the possible spread of cancer.

PCR and immunodiagnostic techniques also support the identification of HPV infections and other abnormalities, improving diagnostic capabilities.

By End User

  • Hospitals and Clinics

  • Laboratories

  • Other End Users

Hospitals and clinics play an important role in the market because they are primary healthcare facilities for diagnosing and managing HPV infections and cervical cancer. These facilities provide screening services, diagnostic procedures, and treatment recommendations. Favorable reimbursement policies and increasing patient visits also support the adoption of HPV and Pap testing.

Regional Insights

North America

North America dominated the HPV testing and Pap test market with a market share of 38.6% in 2025. The region is projected to grow at a CAGR of 15.8% during the forecast period.

High awareness of early cervical cancer diagnosis, established screening guidelines, and favorable healthcare reimbursement policies support regional growth. The presence of leading diagnostic companies and access to advanced healthcare technologies also contribute to market expansion.

For instance, in September 2020, Becton, Dickinson and Company (BD) submitted a Premarket Approval Application to the U.S. FDA for its ThinPrep Pap Test PreservCyt Solution vial and Onclarity HPV Assay.

Europe

Europe is projected to grow at a CAGR of 15.3% during the forecast period. The high incidence of cervical cancer in countries such as Germany, the United Kingdom, France, Italy, and Spain supports regional demand.

According to GLOBOCAN 2020, approximately 58,169 new cervical cancer cases and 25,989 deaths were reported in Europe. Established healthcare infrastructure, screening guidelines, and favorable reimbursement policies are also supporting market growth.

Asia-Pacific

Asia-Pacific is expected to experience significant growth during the forecast period. High rates of HPV infections and cervical cancer in countries such as China, Japan, and India are increasing demand for diagnostic testing.

Government initiatives and public-private partnerships aimed at improving cervical cancer screening are also supporting regional development. Technological innovation and the adoption of AI-based diagnostic solutions are creating additional opportunities.

Latin America and Middle East and Africa

In Latin America, increasing cervical cancer cases in countries such as Brazil, Mexico, and Argentina are supporting demand for screening procedures.

In the Middle East and Africa, government initiatives are improving access to early diagnosis and preventive healthcare. For instance, Rwanda introduced a nationwide cervical cancer prevention program in April 2020, supporting modern molecular HPV screening for women between 35 and 45 years of age.

Key Players Analysis

Key players in the HPV testing and Pap test market include:

  1. Abbott Laboratories

  2. Qiagen N.V.

  3. Quest Diagnostics, Inc.

  4. Hologic, Inc.

  5. Becton, Dickinson and Company

  6. F. Hoffmann-La Roche Ltd.

  7. Arbor Vita Corporation

  8. NURX, Inc.

  9. Femasys, Inc.

  10. Thermo Fisher Scientific, Inc.

  11. Seegene, Inc.

  12. bioMérieux SA

These companies focus on diagnostic innovation, product development, strategic partnerships, and expanding their testing portfolios. Increasing investments in molecular diagnostics and automated screening technologies are helping companies improve testing accuracy and accessibility.

For detailed insights, visit:

https://straitsresearch.com/report/hpv-testing-and-pap-test-market

About Us

Straits Research is a global market intelligence and consulting organization providing industry research reports, business intelligence, and strategic insights across multiple industries. Its research helps organizations understand market trends, identify growth opportunities, evaluate competitive landscapes, and make informed business decisions.

Contact Us

Email: [email protected]

U.S.: +1 646 905 0080

U.K.: +44 203 695 0070